amarin corporation plc -adr
(AMRN:NASDAQ GM)
amarin corporation plc -adr (AMRN) Snapshot
|
Open
$7.10
|
Previous Close
$7.14
|
|
|
Day High
$7.13
|
Day Low
$7.00
|
|
|
52 Week High
07/19/12 - $15.96
|
52 Week Low
04/24/13 - $6.34
|
|
|
Market Cap
1.1B
|
Average Volume 10 Days
4.0M
|
|
|
EPS TTM
$-1.24
|
Shares Outstanding
150.3M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
amarin corporation plc -adr (AMRN) Related Businessweek News
No Related Businessweek News Foundamarin corporation plc -adr (AMRN) Details
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
amarin corporation plc -adr (AMRN) Top Compensated Officers
amarin corporation plc -adr (AMRN) Key Developments
Amarin Corporation plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's product revenues were $2,341,000. Operating loss was $60,051,000 compared to $18,783,000 a year ago. Loss from operations before taxes was $65,415,000 compared to $88,875,000 a year ago. Net and comprehensive loss was $62,158,000 or $0.41 per basic and diluted share compared to $88,258,000 or $0.65 per basic and diluted share a year ago. Adjusted net loss for EPS1 - non GAAP was $61,355,000 or $0.41 per basic and diluted share compared to $15,828,000 or $0.12 per basic and diluted share a year ago.
Amarin Corporation plc announced that they will report Q1, 2013 results at 9:02 PM, GMT Standard Time on May 09, 2013
Amarin Corporation plc, Q1 2013 Earnings Call, May 09, 2013
| Recently Viewed | |||
| AMRN:US | $7.00 USD | -0.1401 |  |
| Company | Last | Change |
| Alkermes PLC | $32.06 USD | +0.365 |
| Dendreon Corp | $3.96 USD | -0.05 |
| Jazz Pharmaceuticals Plc | $58.95 USD | +0.59 |
| Onyx Pharmaceuticals Inc | $96.54 USD | +0.89 |
| Spectrum Pharmaceuticals Inc | $8.11 USD | -0.0299 |
| View Industry Companies | ||
Industry Analysis
AMRN
Industry Average
| Valuation | AMRN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 464.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 277.0x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: Apr 29
Sponsored Financial Commentaries
Sponsored Links
To contact AMARIN CORPORATION PLC -ADR, please visit www.amarincorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
